Notice of Multi-Color First Quarter 2026 Financial Results Conference Call June 4, 2026 Multi-Color Corporation (“MCC”) First Quarter 2026 Financial Results Conference Call covering MCC’s performance for the quarter ending March 31, 2026. When: Monday, June 8th at 10:00 A.M. EDT Leaders: Hassan Rmaile, President & CEO and Kathleen Phelps, CFO Access: Existing and prospective investors can gain access to the investor data site (“Data Site”) by following [...]
Allegion to Attend 2026 Wells Fargo Industrials & Materials Conference June 2, 2026 Allegion plc (NYSE: ALLE) President and CEO John H. Stone will discuss the company’s long-term strategy at the 2026 Wells Fargo Industrials & Materials Conference on Tuesday, June 9. The conference will be held at Loews Chicago Hotel. A live listen-only webcast will be accessible via Allegion’s investor website at investor.allegion.com or directly by clicking [...]
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference May 27, 2026 Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET. A live webcast can be accessed in the Investors section of the [...]
Argan, Inc. to Announce First Quarter Fiscal 2027 Results and Host Conference Call on Thursday, June 4, 2026 May 21, 2026 Argan, Inc. (NYSE: AGX) (“Argan” or the “Company”) today announced that the Company will release its first quarter fiscal 2027 financial results after the market closes on Thursday, June 4, 2026. Management will host a webcast with an accompanying slide presentation and conference call on Thursday, June 4, 2026 at 5:00 p.m. ET. Participants can [...]
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June May 19, 2026 LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on [...]
ReNew Announces Results for the Fourth Quarter and Full Fiscal Year: Reports Highest Ever Net Profit May 18, 2026 Net Profit jumped 2.3x during the year ended March 31, 2026 Increase in net profit driven by higher operating portfolio, lower leverage and growth in manufacturing business Commissioned 2.4GW of capacity, its highest ever, during the year ended March 31, 2026
Allianz Delivers Record Operating Profit in Strong Start to 2026 May 13, 2026 1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Total business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net [...]
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference May 12, 2026 Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. The live webcast can be [...]
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook May 12, 2026 SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 [...]
Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate